
Biomedical generative pre-trained based transformer language model for age-related disease target discovery

By Aarohi Chopra

Background

Motivation




Goal

Large Language Models

1. LLMs?

2. Idea: Next word prediction

3. Medical Context: Disease to genes



Large Language Model Usage

1. Construct Prompt

2. Tokenize

3. Predict Gene



Data

Training Data:


- National Institutes of Health Grants: 9
- PubMed: 15 million

Reference Data

- HUGO Gene Nomenclature Committee
- GeneAge
- ClinicalTrials.gov
- DrugAge
- PubMedQA

| | Number of parameters Texts for train | | |
|--------------------------|--------------------------------------|---|--|
| BioGPT + Grants | 349 million | 15M PubMed abstracts + 900K biomedical grants full texts | |
| BioGPT | 349 million | 15M PubMed abstracts | |
| BioGPT Large PubMedQA | 1.5 billion | 15M PubMed abstracts + PubMedQA dataset | |
| BioGPT Large 1.5 billion | | 15M PubMed abstracts | |

Exploratory Data Analysis



Methods

Embeddings

1. Sample: PubMed abstracts + grant texts

2. Processing: Lowercase + Removing stopwords(NLTK)

3. Embedding: "all-mpnet-base-v2" sentence-transformers model

Training

- 1. Base: BioGPT (347 million parameters)pre-trained on 15 million PubMed abstracts
- 2. Task: Maximize log-likelihood of a next token given the context
- 3. Customize: BipGPT-G additional 2002 thousand grant abstracts
- 4. Details:

Training time: 40 hours

Batch size: 16

Gradient accumulation step: 64 per device on four A5000 GPUs

Adam algorithm with 100 warm-up steps

Learning rate: 5e-5

Prompt Optimization




- 1. Prompt: "Human gene targeted by a drug for treating {DISEASE} is"
- 2. Task: Next word prediction
- 3. Construction parameters settings
- 4. Efficiency Estimation
- 5. Findings:

- Larger prompt length BAD
- Addition of Articles GOOD
- 6. Brute Result: Total Prob_{Target Gene} = Multiplication of all tokens probabilities

Validation

- 1. Analyze the top K values
- 2. ELFC Log Fold Change of Enrichments (occurrence of targets relative to their general frequency the dataset)
- 3. HGPV Hyperg Echne Ci (spore) u= (log 2 u (targets_k * N) by chance or unusually high) k * targets_N
- 4. Higher value $HGPV(score) = -log10 (1 hgcdf(targets_k, k, targets_N, N))$,





Processing Tokenization

- 1. Maximum token limit
- 2. Filtering longer genes
- 3. Prevent skew for abundant non-gene data
- 4. Use cases (based on token length)
 - A. Gene length <= iterations(N)
 - B. Gene length > iterations(N)
- 5. Varying gene length normalization (separate and combined)
- 6. Normalization of Final Probabilities with longer lengths



Results

1. Product/token length (Figure C 1.3 & 2.4)

2. Normalizing individual tokens(each iteration) given $\sum_{\text{all tokens}} = 1$ (Figure C 3.1)

3. Parameter selection

| Normalization version | HGPV | ELFC | AUROC |
|--|------------------|---------------|-----------|
| Probabilities normaliza | ation on each i | teration | |
| Total sum | 5.93 | 4.11 | 0.59 |
| Separate sum | 4.53 | 3.78 | 0.51 |
| Not sum | 1.39 | 1.73 | 0.63 |
| 2. Final probabilities normalization according | to number of | tokens in a g | gene name |
| length Total sum | 0.78 | 0.61 | 0.51 |
| Total sum / length | 5.94 | 4.02 | 0.59 |
| Separate sum / length | 5.59 | 3.83 | 0.57 |
| Not sum / length | 1.71 | 1.97 | 0.63 |
| 3. Variation of the parameter fo | r the final norm | nalization | |
| Total sum / length*parameter (=4) | 5.50 | 3.75 | 0.58 |
| Total sum / length * parameter (=4)**-1 | 5.49 | 3.76 | 0.57 |
| Total sum / length ** length | 5.37 | 3.67 | 0.57 |
| 4. Apply cut-off for the max length | n of tokens in a | gene name | |
| Total sum / token limit (=5) | 5.15 | 3.56 | 0.56 |
| ional solities total mile (-o) | | | |

Total sum / length + token limit (=5)


5.49

3.76

0.57

Target Discovery for Aging

- 1. Top 200 genes were selected
- 2. \cap GenAge database (p < 0.001)
- 3. \cap PubMed database (p < 0.001)
- 4. Gene Ontology (GO) enrichment analysis (FDR adjusted p < 0.01)



LLM Explainability


- 1. Task: Protein Embeddings and graphs
- 2. Hypothesis: Learn not only probabilities also internal associations of word similarities
- 3. Result: Protein [pubmed(~ aging) and BioGPT(aging)] ---- Protein [pubmed(aging) and BioGPT(aging)]

Protein Graphs:



- "The human age-associated gene is the" gene name —> Tokenized_{mean output pooling}
 PyTorch tensor₁₀₂₄ —> Individual proteins
- 2. Source Nodes: Proteins in (PubMed abstract co-mentions) AND (BioGPT aging)
- 3. Target Nodes: Pro(BioGPT aging) & NOT(PubMed abstract co-mentions)
- 4. Random Nodes: Random proteins for main experiment and control values

Graphs Continued



Dual-purpose Disease and Age-Related Targets

| Targets | Protein family | Clinical trial status ¹ | Known as age-related genes ² | Potential dual-purpose candidates ³ | | |
|---------|-----------------------|---------------------------------------|---|--|--|--|
| BRCA1 | Acyltransferase | No | Yes | No | | |
| CCR5 | GPCR | Yes | No | Yes | | |
| EGF | Growth factor | No | Yes | No | | |
| MIP | Generic protein | No | No | No | | |
| PTH | Generic protein | No | No | Yes | | |
| RET | Receptor kinase | Yes | Yes | Yes | | |
| SRC | Tyrosine kinase | Yes | Yes | Yes | | |
| TNF | Tumor necrosis factor | Yes | Yes | Yes | | |
| VHL | Ligase | No | Yes | No | | |

21

Discussion

- 1. Novel: CCR5, W, and PTH (Previous Table)
- 2. After filtering TNF, SRC and RET, and two novel genes, CCR5 and PTH
- 3. TNF -> Age associated inflammation
- 4. SRC -> Targeted by Dasatinib(Senolytic)
- 5. RET -> Higher levels causes thyroid cancer + Increases with age
- 6. CCR5 -> Neuroinflammation + Alzheimer's disease
- 7. PTH -> Osteoporosis + Frailty

References

- 1. https://pubmed.ncbi.nlm.nih.gov/30269508
- 2. https://pubmed.ncbi.nlm.nih.gov/36936271
- 3. https://pubmed.ncbi.nlm.nih.gov/35837482
- 4. https://pubmed.ncbi.nlm.nih.gov/32534441
- 5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564439/

Thank You:)